The latest Business updates from the science industry
by Heather Hobbs Partnership Highlights Growth in Autoantibody Profiling Sector
Global immunodiagnostics group Oncimmune has signed a partnership with Synexa Life Sciences BV, a provider of biomarker analytical and advisory services in translational and clinical research, that will allow for comprehensive characterisation of the B-cell immune response in a wide range of disease and treatment indications.
Both companies will utilise their expertise to improve patient diagnostics and therapeutics and over the next 18 months Synexa plans to sign multiple new contracts with its partners for autoantibody profi ling, that will broaden the business development efforts of Oncimmune’s technology platform.
This new strategic collaboration comes at a time when autoantibody profi ling, which provides a depth and breadth of clinical data to improve response and adverse event (irAE) prediction, patient screening and diagnostic accuracy, is experiencing substantial
interest, with the market segment growing at approximately 27% year-upon-year.
Dr Adam M Hill, CEO of Oncimmune said: “We welcome this exciting initiative with Synexa Life Sciences, who have recognised the recent progress made by our ImmunoINSIGHTS platform.
“The ImmunoINSIGHTS team look forward to the opportunity to deliver high quality, value-adding analysis and interpretation of blood samples for Synexa and its clients, delivering a differentiated service to customers that are yet to engage with our proprietary technology platform.”
More information online:
ilmt.co/PL/lxoE 57343pr@reply-direct.com
Adam Hill
Key Step Progresses CLIA Accreditation Process
Announcing an update with regard to its clinical laboratory’s accreditation process that will enable Parsortix® tests to be used for patient management in the US, liquid biopsy company Angle has now been issued with a Certifi cate of Registration under the Clinical Laboratory Improvement Amendments (CLIA), by The Centers for Medicare and Medicaid Services (CMS).
A Certifi cate of Compliance will follow successful completion of an inspection of the facilities and documentation on the validation of assays to be performed together with associated quality control procedures.
Accreditation of the company’s UK laboratory is also being progressed under parallel processes. The laboratories are intended as accelerators and demonstrators in support of the Company’s strategic marketing plans. It is currently providing research use
services to pharmaceutical and biotech customers running cancer drug trials.
Angle Chief Medical Offi cer, Dr Todd Druley (pictured), commented: “The issuance of a Certifi cate of Registration under CLIA is an important step towards accreditation of our United States clinical laboratory and the roll out of our commercial offerings in the United States with the intended launch of laboratory developed tests for patients. Accreditation will also provide recognition of the qualifi cations of our laboratory and critical assurances to support the growth in our pharma services business.”
More information online:
ilmt.co/PL/KBBX 57472pr@reply-direct.com
Divestment of Animal Health Group Deepens Focus on Core Activities
Clinical stage oncology drug company Avacta has announced the acquisition of its Animal Health division by Vimian Group AB (Vimian. ST). Providing veterinary allergy diagnostic solutions through its laboratory in Wetherby, UK, Avacta also re-sells immunotherapy products from Nextmune, a Vimian Group company, to veterinary clinics across the UK. The business also provides testing kits to veterinary laboratories across Europe.
During March, Avacta Animal Health Ltd was acquired by Nextmune Holdings BV and will be consolidation into Vimian’s Specialty Pharma segment.
Avacta received an upfront payment of £0.9 million and will receive additional deferred consideration of up to £1.4 million dependent on the combined performance of the consolidated business. The Animal Health Division had made an operating loss (prior to an impairment of historic goodwill) of £0.3 million during the year ended 31 December 2020. The carrying value of the Division as at 31 December 2020 was £1.0 million. The sale proceeds will provide further funds for the development of the Group’s Diagnostics and Therapeutics Divisions.
Dr Alastair Smith, Chief Executive Offi cer of Avacta Group said: “The sale of the Avacta Animal Health business allows the Group to focus entirely on growing its core businesses; diagnostics and therapeutics. Having had our Animal Health division since 2009, we are delighted that Vimian will be retaining the entire Avacta Animal Health team and are well placed to grow the business.”
Magnus Kjellberg, CEO of Vimian’s Specialty Pharma segment Nextmune, added: “This acquisition signifi cantly strengthens Nextmune’s competitive position in the UK. With our own laboratory for veterinary allergy diagnostics in the country and a full-service offering covering all veterinary dermatology needs, we see signifi cant opportunities to accelerate sales and improve customer experience in the UK. The cross-selling opportunities via this business existing customer base as well as the increased laboratory capacity for Nextmune are also key components in driving incremental growth.”
More information online:
ilmt.co/PL/3pp0 57474pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
